Company news

NeuroSense Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023

July 16, 2023

NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit

July 10, 2023

NeuroSense CEO Provides Q2 2023 Update

July 5, 2023

NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023

May 31, 2023

NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

May 14, 2023

NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study

May 1, 2023

NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment

April 16, 2023

NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS

March 26, 2023

NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference

March 22, 2023

NeuroSense Announces Year End 2022 Financial Results and Provides Business Update

March 21, 2023

NeuroSense Therapeutics to Participate in BIO-Europe Spring

March 15, 2023

NeuroSense Therapeutics Ltd. to participate in renmark's virtual Non-Deal roadshow series on, Tuesday, March 21 and Tuesday, March 28, 2023

March 13, 2023

NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts

February 12, 2023

NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases

February 8, 2023

NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial

February 7, 2023

NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study

February 5, 2023

NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study

January 18, 2023

NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

November 30, 2022

NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS

November 15, 2022

NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study

November 14, 2022

NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences

October 26, 2022

NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany

October 20, 2022

NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US

September 27, 2022

NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial

September 19, 2022

NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

September 18, 2022

NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update

August 30, 2022

NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study

August 1, 2022

NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study

June 29, 2022

NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

May 31, 2022

NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update

May 30, 2022

NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS

April 10, 2022

NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC

April 5, 2022

NeuroSense Therapeutics Receives $4 Million Through Warrant Exercises

March 24, 2022

NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS

March 20, 2022

NeuroSense Therapeutics, Ltd. Announces the Presentation of Phase IIa Study Results at Four International Conferences

January 3, 2022

NeuroSense Therapeutics Ltd. Expands Board of Directors and Adds Chief Medical Officer to Leadership Team

December 20, 2021

NeuroSense Therapeutics Announces Closing of Initial Public Offering on Nasdaq Capital Market

December 12, 2021

← Newer news releases

Decks

The 5 newest of 18 decks. Every deck is listed under its year.